thank this to the the and joining taking you you afternoon. appreciate to for call [listening]. time everyone Thank you, We Paula,
and we During important a ThermoGenesis a XXXX medical took device to market. for gene steps therapy towards development organization in thus to transform far our plans the cell from manufacturing and company and or CDMO XXXX, executing contract
October business leverage proprietary approximately and planned financing of another semi-automated CDMO processing recently completed the support we which placement $X.X million and finances launch an XXXX, private we and $X.X the transaction. including platforms, CAR-TXpress our million our These In unique will through completed will cell automated platform.
medicines clinics next-generation Our gene accelerate and into goal companies is candidates such and quickly as as cell cancer safely help to develop institutions to drug as to therapies possible.
establish manage risks. supply increasing and chain, focus solutions overall customers streamline to manufacturing will for Our be in to order [predictabilities],
customers the third gene companies available for available be out roll science expect To suites it quarter year. [this] cGMP and announced to that life end, the recently this and in ReadyStart we by second of therapy early-stage cell of to
I automated and long its production the remind has products of progress, cutting-edge cell banking the to Before of to come therapy we ThermoGenesis technologies industry. ability list our and of want you a proven from. and cell where further pioneer into I [devolve] development for
choice For many technologies cell years, most ThermoGenesis and processing has for the smart important storage the public banks. been automated provider of world's some of automated of and private the cryogenic
BioArchive clinical well system has units. blood by samples FDA cord over our AXP million close US world of to processed to XX% the Our all been approved a grade cryo-storage XXX BLA warehoused utilized close And and institutes across approximately thus far. has has system
and focus continued our personalized in intellectual future. The we our on we industry have gene the strategy properties history therapy. invaluable, growth full excited and forward-looking potential the accumulated the is part Driving about and over for is are large cell
Since CAR-T FDA. been XXXX, autologous the approved six by has therapies
standard as CAR-T been initially defense, While its care second-line could CAR-T these trials more expand the therapies were of that can therapies recently, line outperform that future. which approved options, of in applications there the shown have last have
Recent report each as as many XX approvals to shows XXXX. therapies that the industry new starting with in anticipates year, additional XX FDA
have an globally, clinical more US solid for cell asset variety over working in now therapy. And companies of solid continue and gene targeting explode, cell alone the than estimated now in demand are there As tumors. a XXX blood development we to therapies one pipeline
a in outsource though been in fraction and surge over an not in the fortunately, has capacity. manufacturing of production days. of the their manufacturing. XX matched needs, companies to or therapies a commercial critical their marketplace in by coming be months activity exacerbated by gene XX today, increase accelerated XX And capacity clinical creating approvals cell Even all exists will backlog XX% only only the required This in
participants and availability the more therapy increased and for CDMO the in cGMP biopharmaceutical more the led have industrial limited other cell demands and dynamics facilities. partnership of These rise recognize as companies to urgency a of activities the
key growing a same be needs critical cost, global will drugs and process and manual created there by main for due At from time, bedside. faster capacities. to the the these limited from inefficiencies, timelines production unmet contract technological high bench are and facilitating continued challenges forward life-saving manufacturing to getting Moving these to centerpiece of
largest Drug the cell manufacturing today cost is still component CAR-T the therapies. of of
manufacturing As a need there high-quality for a result, significant is a cGMP cost. reasonable at
own Additionally, takes to cell for And facilities. not well process years a build CDMOs that equipped for manufacturing. the is there are companies lot therapy it required are the of gene to handle that their
providing extremely solutions manufacturing development, The by life-saving and lives] other of ThermoGenesis for as as [personal and manufacturing therapeutic for address system, review] and development cell candidates development. clients growing CDMO [cryo important look need need this for Cell cGMP with ever. in and capacities. complex the manufacturing therapies will processing stage regulatory various high-quality of service is to tissue compliance,
Specifically, platform, to unique expertise valuable in-house with we will processing our cell leverage provide such for as technologies existing our CAR-TXpress clients with candidates. combined therapeutic solutions
will deal the services to to specifically needed line the provide uncertainty be of our stage together, at with Taken process. designed flexibility products and every of
in office As our to laboratory we which suites the manufacturing industry's support out building ReadyStart announced, and of recently cGMP California, includes XX,XXX space cleanroom requirements. Sacramento, feet square XX are approximately [class seven]
ReadyStart These life available for cGMP by will science companies. cell this and gene be Suite early-stage therapy
same and/or are looking and in suites to and highest ReadyStart to efforts the the with up turnkey jump-start meet quality regulatory their development for will ideal scale solution. facility the requirements a companies Importantly, early-stage scientific
will the than by Further, companies greatly accelerate the on resource development science. core and allowing eliminate suites burden rather tremendous cycle focus to a
more all-encompassing Suite Our will faster [enable] a flexible cGMP companies their achieve provide ReadyStart to and milestones option anticipated efficiently.
regulatory and expertise development to focus strong allowing products, while them affair our the the customers' compliance help quality science on running GMP team's their ThermoGenesis will and own manage with will regulatory our facility. of Additionally, product accelerate associated in commercialization a
range million. the forward be this reporting $XX the expected progress and The the second look fully of and, of in more additional ReadyStart cGMP to quarter are an on coming annual revenue available $XX for to in once months. in leased, to to customers expected third suites year million the are generate We
for with call year. the turn to over let And financial that, some key Jeff? to me share result of the Jeff the
